Milan-based Newronika said its latest aDBS system features full integration with WebBioBank, its proprietary, cloud-based neural data platform. It builds upon the already CE-marked Newronika aDBS platform for treating Parkinson’s disease.

The company said CE mark represents the first approval for an aDBS system that continuously senses neural activity and automatically adjusts stimulation according to patient-specific adaptive therapy settings, transmitting the data into a fully integrated neural data cloud platform. Its platform understands the brain’s signals and helps to deliver better outcomes. The company aims for fewer side effects, fewer clinical visits and reduced burden on patients and clinicians.